Top Abstract Purchase Related
Home
>
Node
>
Subnode

1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy

Pierides, A.M.; Kerr, D.N.; Ellis, H.A.; Peart, K.M.; O'Riordan, J.L.; DeLuca, H.F.

Clinical Nephrology 3(2): 189-196

1976

ISSN/ISBN: 0301-0430
PMID: 819195
Document Number: 102465
Two regular hemodialysis patients were assessed before, during and after therapy for 8 1/2 months with 1alpha-hydroxycholecalciferol (1alphaOHD3). The first patient (F.S.), treated with 2 mug daily, improved considerably with complete resolution of histological osteomalacia (O.M.), reduction in osteitis fibrosa (O.F.) and healing of Looser zones. The second patient (T.Y.), who was treated at the same time with a combination of phenobarbitone and phenytoin, showed no improvement while taking 3 mug of 1alphaOHD3 daily. It is suggested that hepatic microsomal enzyme inducing drugs antagonize the action of 1alphaOHD3 by interfering with its subsequent hepatic 25-hydroxylation.

Document emailed within 1 workday
Secure & encrypted payments

Sebert, J.L.; Marie, A.; Kuntz, D.; Marie, P.; Gueris, J.; Smadja, A.; Fournier, A.; Quichaud, J. 1981: Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients Revue du Rhumatisme et des Maladies Osteo-Articulaires 48(7-9): 535-541
Masuyama, J.; Tachibana, Y. 1984: Effects of water purification on renal osteodystrophy in the patients with regular hemodialysis therapy Nihon Jinzo Gakkai Shi 26(4): 407-416
Fournier, A.E.; Bordier, P.J.; Gueris, J.; Chanard, J.; Marie, P.; Ferriere, C.; Osario, M.; Bedrossian, J.; de Luca, H.F. 1976: 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association 12: 227-236
Pierides, A.M.; Ellis, H.A.; Ward, M.K.; Simpson, W.; Kerr, D.N. 1977: 1alpha-Hydroxycholecalciferol in renal osteodystrophy Calcified Tissue Research 22(Suppl): 105-111
Postlethwaite, R.J.; Houston, I.B. 1977: 1alpha-Hydroxycholecalciferol in children with renal osteodystrophy Calcified Tissue Research 22(Suppl): 371-375
Okada, K.; Kuno, T.; Yanai, M.; Maeda, H.; Takahashi, S.; Hatano, M. 1988: The effects of CaCO3 on renal osteodystrophy--comparison of patients with chronic renal failure in the predialytic stage and patients undergoing maintenance hemodialysis Nihon Jinzo Gakkai Shi 30(8): 1053-1062
Ishida, M.; Yamada, M. 1991: Calcitonin for therapy of renal osteodystrophy due to long-term hemodialysis in patients with chronic kidney failure Nihon Rinsho. Japanese Journal of Clinical Medicine 49 Suppl: 725-731
Kakuhara, T.; Mizoguchi, M.; Itoh, M.; Nagasawa, M.; Mori, T.; Ohtsuka, K.; Kubota, M.; Minatoguchi, T.; Ohara, K.; Yoshida, M.; Koide, H.; Ohno, J. 1982: Effects of 1 alpha-(OH)D3 on renal osteodystrophy--a 5-year retrospective evaluation Nihon Jinzo Gakkai Shi 24(6): 693-704
Fournier, A.; Tunchot, S.; Bedrossians, J.; Idatte, J.M.; Bordier, P. 1974: Effects of aluminum gels on renal osteodystrophy caused by chronic hemodialysis. Increase in the total surface of osseous resorption in anephric patients La Semaine des Hopitaux: Organe Fonde Par l'Association d'Enseignement Medical des Hopitaux de Paris 50(45): 2803-2810
McGonigle, R.J.; Timmis, A.D.; Keenan, J.; Jewitt, D.E.; Weston, M.J.; Parsons, V. 1981: The influence of 1 alpha-hydroxycholecalciferol on left ventricular function in end-stage renal failure Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association 18: 579-585
Fournier, A.; Bordier, P.; Weil, B.; Safar, M.; Idatte, J.M. 1971: Physiopathology of renal osteodystrophy. II. During chronic hemodialysis and after kidney transplantation La Presse Medicale 79(50): 2291-2296
Fieren, M.; Vermeulen, A.; Mulder, A.W. 1979: Renal osteodystrophy; observations in patients treated with chronic intermittent hemodialysis Nederlands Tijdschrift Voor Geneeskunde 123(8): 289-292
Gerakis, A.; Hadjidakis, D.; Kokkinakis, E.; Apostolou, T.; Raptis, S.; Billis, A. 2000: Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis Journal of Nephrology 13(6): 437-443
Löcsey, L.; Földes, I.; Léhi, M.; Barkai, L. 1982: Histologic and histomorphometric study of bone biopsy material from patients with renal osteodystrophy undergoing hemodialysis Orvosi Hetilap 123(19): 1155-1160
Haldimann, B.; Flury, W. 1977: Treatment of renal osteodystrophy: physiopathology and secondary effects Schweizerische Medizinische Wochenschrift 107(32): 1113-1118
Kolb, E. 1976: Activation of vitamin D 3 and the mode of action of 1,25-hydroxycholecalciferol and 24,25-hydroxycholecalciferol Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 31(15): 561-567
Christiansen, C.; Rødbro, P. 1979: Anticonvulsant-induced osteomalacia. Vitamin D metabolism disorders in epileptics on anticonvulsant therapy Ugeskrift for Laeger 141(5): 280-284
Ramsay, G.; Ledingham, I.M. 1987: Resuscitation in haemorrhagic shock--pulmonary and renal effects: an adverse effect of stabilised plasma protein solution on renal function? Circulatory Shock 22(3): 261-268
Frey, O.R. 2001: Anticonvulsant weaning? how should anticonvulsant therapy be discontinued? Medizinische Monatsschrift für Pharmazeuten 24(8): 266
Pados, G. 1980: Adverse effect of butylbiguanide therapy on alpha-lipoprotein cholesterol levels Orvosi Hetilap 121(41): 2517-2518